Antibodies News and Research

RSS

Omicron has enhanced infectivity that is only weakly neutralized by vaccination or prior infection

Scientists used virus-like particles and found that Omicron showed increased infectivity, relative to the B.1 and B.1.1 strains, which was similar to the Delta variant.

23 Dec 2021

Researchers report loss of antibody potency against SARS-CoV-2 Omicron variant

Researchers find that vaccine-mediated protection against SARS-CoV-2 is significantly reduced against the Omicron variant.

23 Dec 2021

Impact of the rapid spread of the SARS-CoV-2 Omicron variant in Southern Africa

A new study has focused on the genomic profile and early transmission dynamics of Omicron. This study revealed the dominance of the Omicron variant in regions with high levels of population immunity.

23 Dec 2021

Exploring immunity and severe disease caused by the SARS-CoV-2 Omicron variant

A new study describes the findings of a seroprevalence survey intended to establish the infection rates and the incidence of severe COVID-19 through December 15, 2021, in Gauteng, a crowded province that compresses a quarter of the country’s people into less than 2% of its area.

23 Dec 2021

Pediatric hospital admissions rise with omicron SARS-CoV-2 variant

A new study examines the impact of the Omicron variant on hospitalizations among children in South Africa.

23 Dec 2021

Study reports that children develop sustained cross-reactive adaptive immunity against coronaviruses

A new study shows that both antibody and cellular arms of the adaptive immune response against SARS-CoV-2 are displayed strong, sustained, and cross-reactive against other coronaviruses, in young children than the immune responses in adults.

23 Dec 2021

T-cell response to Omicron after an mRNA COVID vaccine booster

In a recent prospective observational study posted to the medRxiv* preprint server, researchers determined Omicron variant-associated T cell responses before and after a third dose of messenger ribonucleic acid (mRNA) vaccination against coronavirus disease (COVID-19) in anti-CD20-treated multiple sclerosis (MS) patients.

22 Dec 2021

Study points toward an alternative drug strategy to stall Alzheimer’s neurodegeneration

Boosting levels of the neurotransmitter norepinephrine with atomoxetine, a repurposed ADHD medication, may be able to stall neurodegeneration in people with early signs of Alzheimer's disease, a study conducted at Emory Brain Health Center suggests.

22 Dec 2021

COVID can affect sperm quality for three months

Researchers determine whether SARS-CoV-2 could cross the blood-testis barrier and be detected in human semen after infection.

22 Dec 2021

rVSV-based bivalent vaccine against SARS-CoV-2 delta variant and influenza

Researchers developed four distinct recombinant vesicular stomatitis virus (rVSV)-based bivalent vaccines against SARS-CoV-2 and influenza virus.

22 Dec 2021

Study confirms coronavirus RNA synthesis occurs inside membrane-bound compartments

Researchers have experimentally proved that virus-related double-stranded RNA (dsRNA) and the sites of viral RNA synthesis are associated with one another.

22 Dec 2021

Importance of booster vaccine doses for maintaining protection against the SARS-CoV-2 Omicron variant

A new study shows that although the Omicron variant exhibits significant immune escape compared to other SARS-CoV-2 variants, antibody neutralization can be largely restored with booster doses of mRNA vaccines.

22 Dec 2021

Omicron evades roughly twice the number of SARS-CoV-2 neutralizing antibodies than Delta

New study results highlight that Omicron has an increased affinity to ACE-2 receptors, therefore, has increased infectivity, viral load, and transmissibility compared to other variants of concern, including the Delta variant.

22 Dec 2021

Extended interval between second and third vaccination beneficial against SARS-CoV-2 Omicron variant

A new study proposes a multi-boost vaccine strategy with a longer duration between the second and third dose, as that would be beneficial in acquiring immunity against severely mutated SARS-CoV-2 variants.

22 Dec 2021

Scientists identify a panel of nanobodies with good neutralizing efficacy against SARS-CoV-2 variants of concern

A team of scientists from Canada has recently characterized a panel of nanobodies against the spike protein of SARS-CoV-2.

22 Dec 2021

Two-dose ChAdOx1 vaccine protection wanes after three months

New research reported in the journal The Lancet examines the temporal association between the two-dose ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccination regimen and the risk of severe outcomes from COVID-19 in Scotland vs. Brazil, where the Delta variant of SARS-CoV-2 was dominant and rare, respectively.

21 Dec 2021

Broad neutralization of SARS-CoV-2 spike protein by an unconventional antibody fragment

A new preprint research paper posted to the bioRxiv* server examines the nature and effects of the spike mutations and identifies a vulnerable point that could help develop broad-spectrum protection against circulating variants.

21 Dec 2021

National U.S trial confirms effectiveness of mRNA COVID-19 vaccines

In a recent study, published in the Annals of Internal Medicine, scientists conducted a target trial emulation study and documented that among the elderly in the U.S. (with significant comorbidities), the efficacy of messenger RNA (mRNA) vaccines was much lower in terms of preventing infection, than previously reported. However, the effectiveness against death was found to be high.

21 Dec 2021

Early administration of SARS-CoV-2 convalescent plasma reduces outpatient hospitalizations

The results of a nationwide, multicenter clinical trial led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health provides solid evidence for the use of plasma from convalescent patients — those who have recovered from the disease and whose blood contains antibodies against SARS-CoV-2, the virus that causes COVID-19 — as an early treatment.

21 Dec 2021

Molecular mechanism of SARS-Cov-2-induced thrombosis

Researchers demonstrate that the exposure of platelets to the SARS-CoV-2 spike protein promotes their activation and adhesion.

21 Dec 2021

Antibodies News and Research

Omicron has enhanced infectivity that is only weakly neutralized by vaccination or prior infection

Researchers report loss of antibody potency against SARS-CoV-2 Omicron variant

Impact of the rapid spread of the SARS-CoV-2 Omicron variant in Southern Africa

Exploring immunity and severe disease caused by the SARS-CoV-2 Omicron variant

Pediatric hospital admissions rise with omicron SARS-CoV-2 variant

Study reports that children develop sustained cross-reactive adaptive immunity against coronaviruses

T-cell response to Omicron after an mRNA COVID vaccine booster

Study points toward an alternative drug strategy to stall Alzheimer’s neurodegeneration

COVID can affect sperm quality for three months

rVSV-based bivalent vaccine against SARS-CoV-2 delta variant and influenza

Study confirms coronavirus RNA synthesis occurs inside membrane-bound compartments

Importance of booster vaccine doses for maintaining protection against the SARS-CoV-2 Omicron variant

Omicron evades roughly twice the number of SARS-CoV-2 neutralizing antibodies than Delta

Extended interval between second and third vaccination beneficial against SARS-CoV-2 Omicron variant

Scientists identify a panel of nanobodies with good neutralizing efficacy against SARS-CoV-2 variants of concern

Two-dose ChAdOx1 vaccine protection wanes after three months

Broad neutralization of SARS-CoV-2 spike protein by an unconventional antibody fragment

National U.S trial confirms effectiveness of mRNA COVID-19 vaccines

Early administration of SARS-CoV-2 convalescent plasma reduces outpatient hospitalizations

Molecular mechanism of SARS-Cov-2-induced thrombosis

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News